Enfortumab Vedotin: 13 agencies, 2022–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The record spans 4 years, opening at AWMSG (Wales) on 3 May 2022 and running to 11 May 2026.
CIPM (Spain) changed its position: not recommended on 13 Apr 2023, recommended by 25 Feb 2026, after a resubmission.
No assessment is on file from PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
Not every gap is a refusal: for enfortumab vedotin, 1 submission was never made and 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 20 of 27 records date from 2023 or later.
7 distinct indication wordings are recorded for enfortumab vedotin by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
3 of these 27 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess enfortumab vedotin, on 3 May 2022; HIRA (South Korea) did not open a file until 2 Apr 2026 — a wide spread of 3.9 years between the earliest and latest system to look at it.
The record arrives in waves: 5 separate years each carry two or more decisions, spread across 5 years in total.
10 of the 13 agencies here assessed enfortumab vedotin more than once, CIPM (Spain) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
enfortumab vedotin has been through 13 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for enfortumab vedotin reads 14 recommended, 5 not recommended, 3 restricted and 1 appraised, with 4 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HIRA (South Korea) | 2 Apr 2026 | 국소 진행성 또는 전이성 요로상피암 성인 환자의 1 차 치료로서 펨브롤리주맙과의 병용요법 | reimbursement appropriate | source |
| AIFA (Italy) | 21 Jan 2026 | Padcev, in associazione a pembrolizumab, è indicato per il trattamento di prima linea di pazienti adulti con cancro urot… | fully innovative · reimbursed class H | source |
| AOTMIT (Poland) | 24 Oct 2025 | programu lekowego „Leczenie pacjentów z rakiem urotelialnym (ICD-10: C61, C65, C66, C67, C68) | recommended conditionally | source |
| CIPM (Spain) | 22 Oct 2025 | Indicaciones terapéuticas autorizadas: LABORATORIO MEDICAMENTO FORMATO CN Criterios para la financiación SANTHERA PHARMA… | not financed by the SNS · art. 92 d | source |
| NICE (England) | 11 Sep 2025 | NICE TA1097 | published appraisal | source |
22 further decisions for enfortumab vedotin, across 12 agencies, are not shown here. They include the most recent record on file, 11 May 2026 from SMC (Scotland); its outcome is in the subscriber dataset. They link to 19 further source documents.
Related molecules
- pembrolizumab — same ATC class L01F — Antineoplastics
- nivolumab — same ATC class L01F — Antineoplastics
- daratumumab — same ATC class L01F — Antineoplastics
- rituximab — same ATC class L01F — Antineoplastics
- bevacizumab — same ATC class L01F — Antineoplastics
- blinatumomab — same ATC class L01F — Antineoplastics
Coverage: 27 decisions for enfortumab vedotin from 13 agencies, 2022 to 2026. Data to 7 Sep 2026. ATC class L01F — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.